Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Lamb Weston Q3 Fiscal 2026 Earnings Call - North America execution masks international pain, cost cuts on track
Lamb Weston reported a mixed quarter. North America drove the beat with customer wins, 12% volume growth and stronger retention, allowing management to tighten guidance and raise the net sales and EBI...
- Company tightened fiscal 2026 guidance, raising the net sales midpoint and narrowing the range; new net sales guidance $6.45B to $6.55B, adjusted EBITDA guidance $1.08B to $1.14B.
- Overall Q3 net sales grew 3% including a $47M FX benefit, while constant currency net sales were essentially flat year over year.
- Total company volume was up 7% in Q3, driven by North America where volume rose 12% and net sales in the segment rose 5%.
- +13 more takeaways
Bit Digital Q4 and Full Year 2025 Earnings Call - Repositioned as SAC focused on Ethereum staking and WhiteFiber AI infrastructure
Bit Digital declared a strategic pivot in 2025, repositioning itself as a Strategic Asset Company built around an Ethereum treasury and staking platform, plus a majority stake in WhiteFiber for AI inf...
- Company repositioned as a Strategic Asset Company centered on Ethereum and AI infrastructure, emphasizing ETH per share and long-term compounding.
- Management began exiting Bitcoin mining, active hash rate was approximately 1.5 exahash at year-end, and no growth or replacement capital will be allocated to mining.
- WhiteFiber is consolidated on Bit Digital’s statements, management holds a majority (about 70%) stake, and they do not intend to monetize that position in 2026.
- +13 more takeaways
PVH Corp Q4 2025 Earnings Call - Margin Resilience and D2C Momentum Despite Rising Tariffs
PVH closed 2025 by beating Q4 guidance on revenue, operating profit and EPS, while signaling a cautious but constructive start to 2026. The company delivered sequential gross margin improvement across...
- Q4 results beat guidance: reported revenue up mid-single digits, flat in constant currency, with Q4 non-GAAP operating margin of 10% and EPS up 17% year over year to $3.82.
- Full year 2025 delivered reported revenue up 3%, non-GAAP operating margin of 8.8%, and EPS of $11.40, ahead of guidance despite tariff disruption.
- Tariff headwind is material and accelerating, management assumes a 15% U.S. tariff effective Feb 24, 2026, and projects approximately $195 million gross tariff cost to EBIT, or roughly $3.30 per share, in 2026.
- +12 more takeaways
Tilray Brands Q3 FY2026 Earnings Call - Record quarter as international cannabis surges and BrewDog deal lifts run-rate toward $1.2B
Tilray reported a record Q3 with net revenue of $206.7 million, driven by a breakout quarter in international cannabis and continued progress across distribution and wellness. Management leaned into t...
- Record Q3 net revenue of $206.7 million, up 11% year-over-year, driven by multi-segment growth across cannabis, distribution, beverage and wellness.
- Gross profit rose to $55 million, a 6% increase year-over-year; gross margin modestly declined to 27% from 28% due to mix and input cost pressures.
- Tilray ended the quarter with $264.8 million of cash, restricted cash and marketable securities and approximately $3.5 million net cash, an improvement of $40.2 million from a year ago when the company was net debt.
- +15 more takeaways
Cal-Maine Foods Q3 FY2026 Earnings Call - Specialty and Prepared Foods Now Drive the Business as Commodity Prices Collapse
Cal-Maine reported a crushing year-over-year revenue and profit reset as wholesale egg prices normalized from last year’s HPAI shock, but the company’s deliberate portfolio shift showed up loud and cl...
- Net sales plunged 53% year-over-year to $667 million, reflecting a sharp unwind from last year’s HPAI-driven price spikes.
- Conventional egg sales collapsed 72.1% year-over-year to $283.2 million, driven primarily by a 70.1% drop in selling prices and a 6.7% decline in volumes.
- Specialty egg sales were down 12.1% to $289.1 million, but volumes rose 5.8% and specialty now represents 50.5% of shell egg sales in Q3, vs 24.4% a year ago.
- +12 more takeaways
VolitionRx Limited Full Fiscal Year 2025 Earnings Call - Clinical commercialization accelerates as NETs and Nu.Q Cancer move into real-world use and Capture-Seq shows >99% pure ctDNA
VolitionRx says 2025 was a pivot year, shifting from R&D into commercialization with tangible, near-term clinical deployments. The company reported its first CE Mark Nu.Q NETs revenues, a first order ...
- Nu.Q NETs included as sole biomarker in DETECSEPS, a French government-backed interventional program worth about $7.3 million, marking imminent real-world clinical use for early sepsis detection.
- Volition received its first order of Nu.Q Cancer assays from Hospices Civils de Lyon for clinical certification ahead of routine clinical use; company targeting reimbursement submission in France and routine use by Q4 2026.
- First commercial revenue recognized from the CE Mark Nu.Q NETs automated assay during 2025, and 12 hospital networks are currently evaluating the assay across 15 clinical use cases.
- +14 more takeaways
Investcorp Credit Management BDC Q4 2025 Earnings Call - Board launches strategic review and pauses dividend after 16% NAV hit
Investcorp Credit Management BDC opened a strategic review and paused its quarterly dividend after a sharp quarter. NAV per share fell to $4.25 from $5.04, a roughly 16% sequential decline driven by f...
- Board formed a special committee of independent directors to review strategic alternatives, no further comment planned during the review.
- Board decided not to declare the quarterly dividend for the current quarter, effectively pausing distributions.
- Net asset value per share declined to $4.25 from $5.04, a roughly 16% sequential drop, primarily due to fair value adjustments and dividend payout in excess of NII.
- +12 more takeaways
MSC Industrial Direct Fiscal 2026 Q2 Earnings Call - Sales-force restructuring knocked volumes, pricing and cost cuts kept margins intact and management expects recovery
MSC reported fiscal Q2 average daily sales growth of 2.9%, missing the midpoint of its outlook after a deliberate, broad consolidation of its sales and service organization. The reorganization, which ...
- Average daily sales (ADS) grew 2.9% year-over-year in fiscal Q2, below the midpoint (4.5%) of the company outlook.
- Volumes declined about 4% year-over-year in Q2; roughly 100 basis points of the decline were attributed to weather and the partial government shutdown.
- Company completed the last structural phase of a sales optimization, consolidating customer-facing roles, with approximately 130 associates impacted by the service model change.
- +12 more takeaways
Synergy CHC Corp. Q4 2025 Earnings Call - One-time charges drove the loss, RTD momentum and Mexico rollouts set 2026 up for growth
Synergy finished 2025 with headline losses driven by a cluster of one-time hits, not an operational collapse. A $2.9 million license reversal, a $6.66 million bad debt allowance, a $1.04 million obsol...
- Q4 2025 net revenue was $6.07 million versus $10.27 million year over year, a 41% decline driven largely by a $2.9 million license revenue reversal tied to the UAE/Turkey agreement termination.
- Excluding the $2.9 million license reversal, Q4 revenue was $8.97 million, a 12.7% decline versus prior year, indicating softer core sales but not a collapse.
- Q4 gross margin plunged to 36.6% from 63.3% a year ago; excluding the license reversal and a $1.04 million obsolete inventory write-off, adjusted gross margin would have been 68.8%, higher than prior year.
- +12 more takeaways
Nanobiotix Full Year 2025 Earnings Call - JNJ Absorbs Phase III Costs, Runway Extended Into 2028 While 2027 Readouts Become Binary Catalysts
Nanobiotix used 2025 to pivot. A reworked licensing deal with Janssen removed the bulk of Nanobiotix’s funding obligation for the NANORAY-312 phase III, producing a one-time accounting revenue uplift ...
- Amended Janssen agreement removed most development funding obligations for NANORAY-312, shifting costs and operational responsibility to Janssen while preserving milestone upside for Nanobiotix.
- Reported positive revenue of EUR 32.6 million in 2025 was driven by a non-recurring EUR 21.8 million accounting recognition tied to the licensing amendment, not recurring commercial sales.
- R&D spend fell to EUR 23.1 million in 2025 from EUR 40.5 million in 2024, largely reflecting the transfer of NANORAY-312 costs to Janssen.
- +12 more takeaways